Stocktoria
CG Oncology, Inc. CGON
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-01-25
CG Oncology, Inc. statistics & valuation
Market cap$6.3B
P / B8.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | -4722.1% | -10067.3% | -27180.9% |
| Net margin | -3985.0% | -7729.5% | -23827.0% |
| FCF margin | -3279.2% | -6931.3% | — |
| Return on assets | -20.3% | -11.7% | -24.4% |
| Return on equity | -21.4% | -12.0% | 39.5% |
| Debt / equity | 0.00× | 0.00× | — |
| Current ratio | 24.63 | 35.30 | 13.62 |
| Revenue growth | 254.7% | 458.3% | — |
Source: SEC EDGAR filings · CIK 0001991792 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.